Creatine Safety & Tolerability in Huntington's Disease

Completed · Phase 2

Conditions studied: Huntington's Disease (HD)

In brief

The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.

Key facts

Study ID

NCT01412151

Run by

Massachusetts General Hospital

People needed

10

Starts

2005-04-01

Expected to finish

2011-11-01

Last updated by the study team

2018-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals who have completed the CREST-UP1 study.
• Individuals who are able to take oral medication.
• Individuals capable of providing informed consent and complying with trial procedures.

You may not qualify if…

• History of known sensitivity or intolerability to creatine.
• Clinical evidence of unstable medical illness in the investigator's judgment.
• Additional eligibility criteria apply.

Where it is running

• Massachusetts General Hospital — Charlestown, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.